People: Cyclacel Pharmaceuticals, Inc. (CYCC.O)

CYCC.O on Consolidated Issue listed on NASDAQ Global Market

2.04USD
9 Feb 2010
Price Change (% chg)

$-0.06 (-2.86%)
Prev Close
$2.10
Open
$2.17
Day's High
$2.19
Day's Low
$2.00
Volume
1,519,683
Avg. Vol
4,127,515
52-wk High
$4.08
52-wk Low
$0.25

view people for:

Summary

Name Age Since Current Position
U'Prichard, David 60 2006 Chairman of the Board
Rombotis, Spiro 50 2006 President, Chief Executive Officer, Director
McBarron, Paul 48 2006 Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Sosnowski, Robert 50 2008 Vice President - Sales & Marketing
Chiao, Judy 49 2006 Vice President - Clinical Development and Regulatory Affairs
Henney, Christopher 68 2006 Director
Spiegelman, Daniel 50 2004 Director
Banham, John 68 2006 Director
Bacopoulos, Nicholas 60 2008 Director
» Insider Trading

Biographies

Name Description
U'Prichard, David Dr. David C. U'Prichard is the Chairman of the Board of Cyclacel Pharmaceuticals, Inc. Dr. U’Prichard joined the Board of Directors of Cyclacel in May 2004. He is currently President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe. He is also a Venture Partner with Red Abbey Venture Partners, private equity providers. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Management of Zeneca Pharmaceuticals; General Manager, Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He is a director of Life Technologies, Inc. and Silence Therapeutics plc. He is the non-executive Chairman of Oxagen Ltd. He was Chairman of the Pennsylvania Biotechnology Association in 2004-2005. From 1992 to 1997 he was a member of the board of the Biotechnology Industry Organization (BIO). He received a B.Sc. in Pharmacology from University of Glasgow in 1970 and a Ph.D. in Pharmacology from University of Kansas in 1975.
Rombotis, Spiro Mr. Spiro Rombotis is President and Chief Executive Officer and Director of Cyclacel Pharmaceuticals, Inc. Mr. Rombotis joined Cyclacel in August 1997 and has over 25 years of experience with pharmaceutical and biotechnology companies. He was previously Vice President of International Operations and Business Development; Managing Director, Europe; and Director, Japanese joint venture, at The Liposome Company, Inc. Mr. Rombotis also served as Vice President, Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at Bristol-Myers Squibb Company. He was Head of European Marketing and Sales and Head of Corporate Development at Centocor, Inc. as well as working in Business Development at Novartis AG. He holds a B.A. from Williams College and an M.B.A. and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management where he serves on the Kellogg Biotech Advisory Board.
McBarron, Paul Mr. Paul McBarron is Chief Operating Officer, Executive Vice President - Finance, Secretary and Director of Cyclacel Pharmaceuticals, Inc. Mr. McBarron joined Cyclacel in January 2002 and has over 16 years of experience as a financial executive with pharmaceutical and biotechnology companies. Since 1996, he was a senior member of the finance team at Shire Pharmaceuticals Group plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company employing fewer than 100 people. He was previously employed in various financial positions at Sterling Drug, Inc. and SmithKline Beecham Pharmaceuticals and qualified as a chartered accountant with Ernst & Young.
Sosnowski, Robert Mr. Robert Edward Sosnowski serves as Vice President - Sales & Marketing of Cyclacel Pharmaceuticals, Inc. Mr. Sosnwski joined Cyclacel in April 2008 and has more than 20 years experience in sales and marketing roles in several pharmaceutical companies. Prior to joining Cyclacel, Mr. Sosnowski held the position of Senior Thought Leader Liaison at Genentech, responsible for building advocacy with Key Opinion Leaders. Previously, he was President, CEO and Founding Partner with Dexgen Pharmaceuticals, after holding senior sales and marketing roles with Centocor, Inc., The Liposome Company and Amgen. Mr Sosnowski earned his Bachelor of Science degree in 1980 from the University of Connecticut.
Chiao, Judy Dr. Judy Chiao serves as Vice President - Clinical Development and Regulatory Affairs of Cyclacel Pharmaceuticals, Inc. Dr. Chiao joined Cyclacel in December 2004. From September 2002 to December 2004, she was at Aton Pharma, Inc., a wholly owned subsidiary of Merk & Co., laterally as Vice President, Oncology Clinical Research and Development. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of SAHA, a histone deacetylase inhibitor, for hematologic and solid tumor indications. From July 2000 to December 2001, Dr. Chiao was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency’s primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA’s views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao earned her Bachelor of Science in Chemistry (summa cum laude) at Columbia University, New York, and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center both in New York City. She has also been a member of a number of FDA-related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement (CRADA) on clinical trial simulation and population pharmacokinetic analysis software for drug development.
Henney, Christopher Dr. Christopher S. Henney serves as Director of Cyclacel Pharmaceuticals, Inc. Dr. Henney had served as one of Xcyte’s directors since March 2005, and continued on as Vice Chairman of the Company. Previously, Dr. Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to January 2003, Dr. Henney was Chairman and Chief Executive Officer of Dendreon Corporation. Dr. Henney currently serves as Chairman of Oncothyreon, Inc. and is a director of AVI BioPharma Inc. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham and a D.Sc. from the same university for contributions to the field of immunology.
Spiegelman, Daniel Mr. Daniel K. Spiegelman is a Director of Cyclacel Pharmaceuticals, Inc. Mr. Spiegelman had served as one of Xcyte’s directors since September 2004, and continued on as a director of the company. Mr. Spiegelman has served as the Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc. since September 1999. From January 1998 to September 1999, Mr. Spiegelman served as the Vice President and Chief Financial Officer of CV Therapeutics, Inc. From 1991 until 1998, Mr. Spiegelman was employed by Genentech, Inc., a biotechnology company, holding various positions in the Treasury department, including the position of Treasurer from 1996 to 1998. Mr. Spiegelman also serves as a member of the board of directors of Affymax, Inc. and Oncothyreon, Inc., both publicly-traded biopharmaceuticals companies. Mr. Spiegelman holds a B.A. in Economics from Stanford University and an M.B.A. from Stanford Graduate School of Business.
Banham, John Sir John Banham is a Director of Cyclacel Pharmaceuticals, Inc. Sir John Banham is currently Chairman of Spacelabs Healthcare, Inc. and Chairman of Johnson Matthey plc, senior non-executive director of AMVESCAP plc and non-executive director of Merchant Trust plc. He is past Director General of the Confederation of British Industry (CBI) and past Chairman of Whitbread plc, Geest plc, ECI Partners LLP, Tarmac plc and Kingfisher plc. His public sector appointments comprise first Controller of the Audit Commission and first Chairman of the Local Government Commission for England. He was formerly Honorary Treasurer of the United Kingdom’s Cancer Research Campaign prior to its merger with Imperial Cancer Research. He is a graduate of Cambridge University in Natural Sciences and has honorary degrees from a number of British universities.
Bacopoulos, Nicholas Dr. Nicholas G. Bacopoulos is Director of Cyclacel Pharmaceuticals, Inc. since September 2008. He is currently a consultant to biotech and pharmaceutical companies. His previous leadership roles include CEO and President of Aton Pharma, where he led the development of Zolinza®, approved for the treatment of cutaneous T-cell lymphoma. Aton was subsequently acquired by Merck. He was previously President and Head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva®, approved for the treatment of non-small cell lung cancer and pancreatic cancer. Dr. Bacopoulos also worked for 17 years at Pfizer, where he held senior positions within Pfizer Central Research and Corporate Strategic Planning. He led the company’s Cancer and Neuroscience Research groups, which developed several marketed drugs, including Geodon® and Zoloft®, and produced a significant pipeline of oncology drug candidates, several of which are in clinical trials. Dr. Bacopoulos is currently a consultant to various biotech and pharmaceutical companies. He also serves on the Board of Directors of Mersana Therapeutics, Inc. and Medexis Biotech, S.A., both privately-held biotechnology companies. He received his B.A. degree from Cornell College and his Ph.D. from the University of Iowa. He completed additional coursework and obtained a postdoctoral fellowship at Yale University School of Medicine.

Basic Compensation

Name Fiscal Year Total
U'Prichard, David --
Rombotis, Spiro 1,074,880
McBarron, Paul 614,929
Sosnowski, Robert --
Chiao, Judy 617,782
Henney, Christopher --
Spiegelman, Daniel --
Banham, John --
Bacopoulos, Nicholas --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
AUSTIN W MARXE ET AL 232,487 $1.54
AUSTIN W MARXE ET AL 108,900 $1.14
MORGAN STANLEY 328,850 $0.80
MORGAN STANLEY 47,050 $0.86
MORGAN STANLEY 24,100 $0.86
MORGAN STANLEY 103,172 $0.88
MORGAN STANLEY 4,300 $0.87
MORGAN STANLEY 4,300 $0.87
AUSTIN W MARXE ET AL 1,000 $0.84
MORGAN STANLEY 57,200 $0.90
MORGAN STANLEY 57,200 $0.90
AUSTIN W MARXE ET AL 5,900 $0.84
AUSTIN W MARXE ET AL 39,000 $0.84
AUSTIN W MARXE ET AL 100,300 $0.83
AUSTIN W MARXE ET AL 90,100 $0.84
MORGAN STANLEY 7,200 $0.87
MORGAN STANLEY 7,200 $0.87
AUSTIN W MARXE ET AL 70,000 $0.84
AUSTIN W MARXE ET AL 39,266 $0.84
MORGAN STANLEY 7,400 $1.15
MORGAN STANLEY 7,400 $1.15
MORGAN STANLEY 3,200 $0.61
MORGAN STANLEY 3,200 $0.61
MORGAN STANLEY 81,520 $0.32
MORGAN STANLEY 53,900 $0.36
» Full list on Insider Trading
view people for: